 SAN DIEGO, Nov. 12, 2020 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. NASDAQ: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the third quarter ended Sept. 30. 